Contribution to a book

FZJ-2022-04753

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png PET and SPECT Imaging of Neurodegenerative Diseases

Drzezga, A.FZJ* ; Bischof, G. ; Giehl, K. ; Eimeren, T. v.

2021
Elsevier Amsterdam

Abstract: Today, a number of complementary molecular imaging methods are at our disposal, which can make a relevant contribution to early diagnosis, differential diagnosis, disease monitoring, and follow-up of neurodegenerative diseases. This includes long-established FDG-PET which provides valuable information on location and extent of pathology and has demonstrated great value for early diagnosis, short-term prognosis, and for differential diagnosis of various disorders on the basis of the endophenotype of disease. Imaging of the dopaminergic system has proven value in the workup of movement disorders. More recently introduced, amyloid-PET for the first time allows in vivo diagnostic assessment of a molecular neuropathology, most valuable for verification or exclusion of Alzheimer disease (AD), independent of the symptomatic appearance. Finally, new tracers for tau-PET imaging may allow the assessment of location, extent, and specific type of pathology, which may hold great value for early and differential diagnosis of neurodegeneration in the future.

Note:

---

Contributing Institute(s):

1. Molekulare Organisation des Gehirns (INM-2)

Research Program(s):

1. 5252 - Brain Dysfunction and Plasticity (POF4-525) (POF4-525)
2. 5253 - Neuroimaging (POF4-525) (POF4-525)

Appears in the scientific report 2022

---